抗乙酰胆碱受体抗体浓度相对变化率与achr - ab阳性重症肌无力复发相关

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-04-24 DOI:10.1016/j.cca.2025.120330

Jingluan Tian , Xiaoling Zhou , Feng Zhu , Xinyi Xiao , Hairong Ma , Xin Wang , Yanzheng Gu , Yueping Shen , Xingshun Xu , Qun Xue

{"title":"抗乙酰胆碱受体抗体浓度相对变化率与achr - ab阳性重症肌无力复发相关","authors":"Jingluan Tian , Xiaoling Zhou , Feng Zhu , Xinyi Xiao , Hairong Ma , Xin Wang , Yanzheng Gu , Yueping Shen , Xingshun Xu , Qun Xue","doi":"10.1016/j.cca.2025.120330","DOIUrl":null,"url":null,"abstract":"<div><h3>Backgrounds</h3><div>Myasthenia gravis (MG) is an autoimmune disease predominantly caused by anti-acetylcholine receptor antibodies (AChR-Abs). In this study, the relationship between MG relapse and AChR-Abs concentration were investigated.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the clinical records of 41 patients with AChR-Abs-positive MG. Data collected included age, sex, MG status within 12 months (untreated status, UTMG; recurrence status, RCMG), MG subgroups, QMGs, AChR-Abs concentration and treatments. The relative change rate (RCR) of AChR-Abs concentration was calculated as: RCR(%)=(AChR-Abs–AChR-Abs<sub>UTMG</sub>)/AChR-Abs<sub>UTMG</sub>/month*100. ROC curve analysis and binary logistic regression analyses were used to evaluate the association between these factors and MG recurrence.</div></div><div><h3>Results</h3><div>Within 12 months, 12 patients experienced a recurrence (RCMG). A weak correlation was observed between AChR-Abs level in UTMG and QMGs (r = 0.336, <em>p</em> = 0.032). MG subgroups, QMGs, AChR-Ab levels and RCR differed significantly between RCMG and non-RCMG group. Single factor ROC curves indicated that AChR-Abs concentration, RCR and MG subgroups were related to MG recurrence (AUC = 0.724, 0.736, 0.736). Combining with RCR and MG subgroups, the ROC yielded an AUC of 0.899, demonstrating high sensitivity and specificity.</div></div><div><h3>Conclusion</h3><div>RCR of AChR-Abs was correlated with MG progression, and repeated AChR-Abs measurements can assist in monitoring disease status and guiding therapeutic decision-making.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"574 ","pages":"Article 120330"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients\",\"authors\":\"Jingluan Tian , Xiaoling Zhou , Feng Zhu , Xinyi Xiao , Hairong Ma , Xin Wang , Yanzheng Gu , Yueping Shen , Xingshun Xu , Qun Xue\",\"doi\":\"10.1016/j.cca.2025.120330\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Backgrounds</h3><div>Myasthenia gravis (MG) is an autoimmune disease predominantly caused by anti-acetylcholine receptor antibodies (AChR-Abs). In this study, the relationship between MG relapse and AChR-Abs concentration were investigated.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the clinical records of 41 patients with AChR-Abs-positive MG. Data collected included age, sex, MG status within 12 months (untreated status, UTMG; recurrence status, RCMG), MG subgroups, QMGs, AChR-Abs concentration and treatments. The relative change rate (RCR) of AChR-Abs concentration was calculated as: RCR(%)=(AChR-Abs–AChR-Abs<sub>UTMG</sub>)/AChR-Abs<sub>UTMG</sub>/month*100. ROC curve analysis and binary logistic regression analyses were used to evaluate the association between these factors and MG recurrence.</div></div><div><h3>Results</h3><div>Within 12 months, 12 patients experienced a recurrence (RCMG). A weak correlation was observed between AChR-Abs level in UTMG and QMGs (r = 0.336, <em>p</em> = 0.032). MG subgroups, QMGs, AChR-Ab levels and RCR differed significantly between RCMG and non-RCMG group. Single factor ROC curves indicated that AChR-Abs concentration, RCR and MG subgroups were related to MG recurrence (AUC = 0.724, 0.736, 0.736). Combining with RCR and MG subgroups, the ROC yielded an AUC of 0.899, demonstrating high sensitivity and specificity.</div></div><div><h3>Conclusion</h3><div>RCR of AChR-Abs was correlated with MG progression, and repeated AChR-Abs measurements can assist in monitoring disease status and guiding therapeutic decision-making.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"574 \",\"pages\":\"Article 120330\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125002098\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002098","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景重症肌无力（MG）是一种主要由抗乙酰胆碱受体抗体（AChR-Abs）引起的自身免疫性疾病。本研究探讨了MG复发与AChR-Abs浓度的关系。方法回顾性分析41例achr - ab阳性MG患者的临床资料。收集的数据包括年龄、性别、12个月内的MG状态(未治疗状态、UTMG；复发状态，RCMG)， MG亚组，qmg， AChR-Abs浓度和治疗。计算AChR-Abs浓度的相对变化率（RCR）为：RCR(%)=(AChR-Abs - AChR-AbsUTMG)/AChR-AbsUTMG/月*100。采用ROC曲线分析和二元logistic回归分析评价这些因素与MG复发的关系。结果12个月内，12例患者出现复发（RCMG）。UTMG与qmg患者AChR-Abs水平呈弱相关（r = 0.336, p = 0.032）。MG亚组、qmg、AChR-Ab水平和RCR在RCMG组和非RCMG组之间差异有统计学意义。单因素ROC曲线显示，AChR-Abs浓度、RCR和MG亚组与MG复发相关（AUC = 0.724, 0.736, 0.736）。结合RCR和MG亚组，ROC的AUC为0.899，具有较高的敏感性和特异性。结论AChR-Abs的rcr与MG进展相关，反复检测AChR-Abs有助于监测病情，指导治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients

Backgrounds

Myasthenia gravis (MG) is an autoimmune disease predominantly caused by anti-acetylcholine receptor antibodies (AChR-Abs). In this study, the relationship between MG relapse and AChR-Abs concentration were investigated.

Methods

We retrospectively reviewed the clinical records of 41 patients with AChR-Abs-positive MG. Data collected included age, sex, MG status within 12 months (untreated status, UTMG; recurrence status, RCMG), MG subgroups, QMGs, AChR-Abs concentration and treatments. The relative change rate (RCR) of AChR-Abs concentration was calculated as: RCR(%)=(AChR-Abs–AChR-Abs_UTMG)/AChR-Abs_UTMG/month*100. ROC curve analysis and binary logistic regression analyses were used to evaluate the association between these factors and MG recurrence.

Results

Within 12 months, 12 patients experienced a recurrence (RCMG). A weak correlation was observed between AChR-Abs level in UTMG and QMGs (r = 0.336, p = 0.032). MG subgroups, QMGs, AChR-Ab levels and RCR differed significantly between RCMG and non-RCMG group. Single factor ROC curves indicated that AChR-Abs concentration, RCR and MG subgroups were related to MG recurrence (AUC = 0.724, 0.736, 0.736). Combining with RCR and MG subgroups, the ROC yielded an AUC of 0.899, demonstrating high sensitivity and specificity.

Conclusion

RCR of AChR-Abs was correlated with MG progression, and repeated AChR-Abs measurements can assist in monitoring disease status and guiding therapeutic decision-making.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.